Global Multiple Sclerosis Drugs Market Size

Multiple Sclerosis Drugs Market 2021 by Drug Class (Immune modulator, Immune suppressant, Interferon, Others), by Route of Administration (Oral , Injection , Intravenous , Infused , Others), by Distribution Channel (Hospital pharmacy, Retail pharmacy, Online stores) Forecast to 2027

  • Report ID: BMRC 1031 | Number of pages: 200 | Published Date: Apr 2020
    Status: Published | Category: Healthcare | Delivery Timeline: 48 hrs

COVID-19
To know the impact of COVID-19 On Multiple Sclerosis Drugs Market 2021 by Drug Class (Immune modulator, Immune suppressant, Interferon, Others), by Route of Administration (Oral , Injection , Intravenous , Infused , Others), by Distribution Channel (Hospital pharmacy, Retail pharmacy, Online stores) Forecast to 2027 Market

Request Now
Market Size Forecast Scenarios (Optimistic, Baseline and Pessimistic) 2021-2027

"Multiple Sclerosis Drugs Market is valued at USD 23950.39 Million in 2018 and expected to reach USD 36251.02 Million by 2025 with the CAGR of 6.10% over the forecast period."

Rising demand for research and developments related to the new drug discovery as well as rising mergers & acquisitions with huge investment for the treatment of multiple sclerosis are some important factor driving the growth of multiple sclerosis drugs market.

Scope of the Multiple Sclerosis Drugs Market Report:

Multiple sclerosis (MS) is a nervous system disease which affects & disrupts communication between spinal cord and the brain. MS damages the myelin sheath which is insulating layer of the nervous system of the body. Myelin sheath is a surrounds and protects human nerve cells. This damage blocks messages between brain and the body and leads to the symptoms of MS. Some of the major symptoms of MS include thinking and memory problems, vision loss, pain, fatigue and impaired coordination, problem in coordination & balancing of the body and muscle weakness. These symptoms vary from person to person and mostly the chances of MS are higher in women than in men which occur in the age group of 20 to 40. Physiotherapy and certain type of drug medications help in suppressing the immune system and slower disease progression. The most common drugs used for the treatment of MS are Avonex, Betaseron, Copaxone, Extavia, Glatiramer Acetate Injection, Aubagio , Gilenya, Mavenclad, Mayzent whereas in infused drugs include Lemtrada Novantrone, Ocrevus and many others. There are certain forms of MS diseases i.e. elapse-remitting and primary-progressive which can be cured by using anti-inflammatory, immunosuppressive drugs and steroids.

The global multiple sclerosis drugs services market is segmented on the basis of drug class, route of administration, distribution channel and region. Based on drug class the global multiple sclerosis drugs market is segmented into immune modulator, immune suppressant, interferon, others. Based on route of administration the multiple sclerosis drugs market is segmented by oral, injection, intravenous, infused and others. Based on distribution channel the multiple sclerosis drugs market is segmented by hospital pharmacy, retail pharmacy, and online stores.

The regions covered in global multiple sclerosis drugs market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Multiple Sclerosis Drugs Companies:

Global multiple sclerosis drugs market reports cover prominent players,

  • F. Hoffmann-La
  • Novartis AG
  • Roche Ltd
  • Biogen
  • Sanofi
  • Bayer
  • GlaxoSmithKline
  • Teva Pharmaceutical
  • Merck
  • Serono
  • Pfizer
  • Abbvie
  • Biogen Idec
  • AB Science
  • Opexa a
  • Others

Multiple Sclerosis Drugs

Global Multiple Sclerosis Drugs Services Market Dynamics –

 The key factor for growth of global multiple sclerosis drugs market is the rise of demand in the market by pharmaceutical and biotechnological companies with surge in research and development activities including various clinical trials for advanced new drugs against MS disease with huge investment. Recently Biogen the major pharmaceutical drugs manufacturing company had bought a brain disorder drug helpful to treat neurological and inflammatory conditions including MS for USD 217 million. In addition to this, according to the report of Pharmaceutical Research and Manufacturers of America in 2009, America’s pharmaceutical research and biotechnology companies holds huge investment in pharmaceutical R&D with USD 65.3 billion spent on R&D, including USD 45.8 billion by PhRMA members alone and has been risen up to USD 1.1 trillion with rising number of clinical trials with producing new 7000 drugs by the year 2019. However, global multiple sclerosis drugs market can be hampered by the high investment require to manufacture new drugs, patent expiry as well as strict government rule and regulations. Moreover rising focus on biological medicines with technological advancement using artificial intelligence, nano-technology for the clinical drugs manufacturing may form the huge opportunity to fuel the global multiple sclerosis drugs market during the forecast period as specialty medicines require scientific expertise and researchers.

Multiple Sclerosis Drugs Market Regional Analysis –

North America is dominating the multiple sclerosis drugs market with the potential rate due to presence of biopharmaceutical, and pharmaceutical companies for clinical research studies. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), U.S. firms has more than half of the world's Research & Development  in pharmaceuticals spending USD 75 billion and hold the intellectual property rights on most new medicines through its advanced contract based clinical research. The U.S. has the substantial overall economic impact of the biopharmaceutical industry which accounted for more than USD 1.3 trillion in economic output, representing 4 percent of total U.S. output in 2015 alone. This biopharmaceutical businesses economic impact has revenue generated in 2015 was USD 558 billion.

Europe is the second-largest region for dominating the growth of multiple sclerosis drugs due to rise  cases of diseases like multiple sclerosis, cardiovascular diseases, cancer etc. as well as surge in investment in R&D for treatment of this diseases in this region. According to European Federation of Pharmaceutical Industries and Associations in 2017, the Europe had invested an around Euro 35,200 million in Research & Development.

The Asia Pacific is expected to emerge as the fastest-growing regional market due to rapidly increasing manufacturing companies, availability of labor at lower cost as well as rising population in this region. The growth for the multiple sclerosis drugs services market is more probable in the developing countries including India and China as availability of resources, labor and many other at cheaper cost.

Report Analysis Details
Historical data 2015 - 2020
Forecast Period 2021 - 2027
Market Size in 2020: USD 23950.39 Million
Base year considered 2020
Forecast Period CAGR %:

6.10 %

Market Size Expected in 2027: USD 36251.02 Million
Tables, Charts & Figures: 175
Pages 200
Key Players/Companies F. Hoffmann-La,Novartis AG,Roche Ltd,Biogen,Sanofi,Bayer,GlaxoSmithKline,Teva Pharmaceutical,Merck,Serono,Pfizer,Abbvie,Biogen Idec,AB Science,Opexa a,Others
Segments Covered By Drug Class, By Route of Administration, by Distribution Channel
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for multiple sclerosis drugs Market Reports –

Global multiple sclerosis drugs market report covers in depth historical and forecast analysis.

Global multiple sclerosis drugs market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global multiple sclerosis drugs market report helps to identify opportunities in market place.

Global multiple sclerosis drugs market report covers extensive analysis of emerging trends and competitive landscape.

Multiple Sclerosis Drugs Market Segmentation –

by Drug Class: Immune modulator, Immune suppressant, Interferon, Others

by Route of Administration: Oral, Injection, Intravenous, Infused, Others

by Distribution Channel: Hospital pharmacy, Retail pharmacy, Online stores

Regional & Country Analysis
North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa


Frequently Asked Questions (FAQ) :
"Multiple Sclerosis Drugs Market is valued at USD 23950.39 Million in 2018 and expected to reach USD 36251.02 Million by 2025 with the CAGR of 6.10% over the forecast period."
North America is dominating the multiple sclerosis drugs market with the potential rate due to presence of biopharmaceutical, and pharmaceutical companies for clinical research studies
F. Hoffmann-La,Novartis AG,Roche Ltd,Biogen,Sanofi,Bayer,GlaxoSmithKline,Teva Pharmaceutical,Merck,Serono,Pfizer,Abbvie,Biogen Idec,AB Science,Opexa a,Others
Rising demand for research and developments related to the new drug discovery as well as rising mergers & acquisitions with huge investment for the treatment of multiple sclerosis are some important factor driving the growth of multiple sclerosis drugs market.



Interested in this report?

Multiple Sclerosis Drugs Market Size, Worldwide Demand and Analysis 2021 and Analysis 2019-2025

report cover

Multiple Sclerosis Drugs Market 2021 by Drug Class (Immune modulator, Immune suppressant, Interferon, Others), by Route of Administration (Oral , Injection , Intravenous , Infused , Others), by Distribution Channel (Hospital pharmacy, Retail pharmacy, Online stores) Forecast to 2027

Note: For delivery of sample pages you must have a Domain Specific Email ID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc. are not accepted.

    Pricing


+44-1173181773
vishal@brandessenceresearch.com


Looking for Regional Reports?